Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 03, 2015 7:11 AM ET


Company Overview of Oryzon Genomics S.A.

Company Overview

Oryzon Genomics S.A., a biopharmaceutical company, develops and commercializes biomarkers identified through genomics and proteomics in the fields of diagnostics, personalized medicine, and therapy. Its products pipeline comprises GynEC-DX, a diagnostic test for endometrial cancer; ColoBRAF, a genetic test that verifies the presence of the BRAF-V600E mutation in MSI-H tumors; and Cxbladder, a non-invasive bladder cancer diagnostic test. The company also develops small molecules and monoclonal antibodies for various indications, including leukemia and other cancers, PD/AD and other dementias, Huntington, viral infections, squamous cell cancer, prostate cancer, and endometrial cancer. In addit...

Sant Ferran 74

Cornellà de Llobregat

Barcelona,  08940


Founded in 2000


34 93 515 13 13


34 93 377 40 28

Key Executives for Oryzon Genomics S.A.

Co-Founder, Chairman, Chief Executive Officer, President and Member of Financial Advisory Board
Co-Founder, Scientific Director and Director
Global Chief Financial Officer, Executive Vice President, Director and Chairman of Audit Committee
Chief Intellectual Property Officer
Director of Business Development
Compensation as of Fiscal Year 2014.

Oryzon Genomics S.A. Key Developments

Oryzon Genomics SA Appoints Greg Weaver as Executive Vice President and Global Chief Financial Officer

Oryzon Genomics SA announced the appointment of Gregory L. Weaver as executive vice president and chief financial officer, effective January 12, 2015. Weaver will report directly to Carlos Buesa, president and chief executive officer of Oryzon, and will be based at Oryzon's U.S. headquarters, located at 245 First Street in Cambridge, MA. Weaver has served as CFO Fibrocell Science. Previous to Fibrocell, Weaver was CFO at Celsion Corp, Poniard Pharmaceuticals and Sirna Therapeutics. He also currently serves as non-executive director of Egalet Corporation and Atossa Genetics. Oryzon's Mr. Enric Rello will remain as CFO in Spain and will continue as part of Oryzon's senior management team to support the company's financial operations in Spain.

Oryzon Genomics S.A. Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 10:45 AM

Oryzon Genomics S.A. Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 10:45 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Oryzon Genomics S.A. Presents at EPIC Biotech 2014, Oct-02-2014 04:00 PM

Oryzon Genomics S.A. Presents at EPIC Biotech 2014, Oct-02-2014 04:00 PM. Venue: The King's Fund, 11-13 Cavendish Square, London, W1G 0AN, United Kingdom.

Similar Private Companies By Industry

Company Name Region
Intersuero, S.A. Europe
Advanced Marker Discovery, S.L. Europe
CZ Veterinaria, S.L. Europe
ResBioAgro, S.L. Europe
Vivia Biotech S.L. Europe

Recent Private Companies Transactions

June 13, 2014
Oryzon Genomics S.A., Diagnostics Business

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Oryzon Genomics S.A., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at